AbstractHere it is described the synthesis, antioxidant and antimicrobialactivity determination of novel rel-(\(5R,6S,7R\))-6-benzoyl-7-phenyl-2-oxo-3,5,6,7-tetrahydro-2H-thiopyrano[2,3-d]thiazole-5-carboxylic acids. The target compounds were obtained in good yields from 5-arylidene-4-thioxo-2-thiazolidinones and \(\upbeta \)-aroylacrylic acids via regio- and diastereoselective hetero-Diels–Alder
抽象的这里描述了新型rel-(\(5R,6S,7R \))-6-苯甲酰基-7-苯基-2-氧代-3,5,6,7-四氢-的合成,抗氧化剂和抗菌活性的测定2 H-硫代吡喃并[2,3 - d ]噻唑-5-羧酸。通过区域-和非对映选择性的杂-Diels-Alder反应,从5-芳叉基-4-硫代-2--2-噻唑烷酮和\(upbeta \)-芳酰基丙烯酸以高收率获得了目标化合物。通过NMR光谱证实了环加成的立体化学。进行抗氧化和抗菌活性筛选,鉴定出7种化合物(3c,3e,3f,3g,3k,3l,3p)具有高水平的自由基清除能力(43-77%DPPH测定),以及对金黄色葡萄球菌,枯草芽孢杆菌和白色念珠菌有显着影响的化合物(MIC 3.13-6.25 \(\ upmu \ hbox g / mL} \)),但对大肠杆菌有轻微影响。 图形概要
Thiazolidinone/thiazole based hybrids – New class of antitrypanosomal agents
have been investigated as potent drugs for trypanosomiasis treatment, but no new drug has been marketed in the past 3 decades. 4-Thiazolidinone/thiazole as privileged structures and thiosemicarbazides cyclic analogs are well known scaffolds in novel antitrypanosomal agent design. We present here the design and synthesis of new hybrid molecules bearing thiazolidinone/thiazole cores linked by the hydrazone
已经研究了各种化合物作为治疗锥虫病的有效药物,但是在过去的30年中,没有新的药物上市。4-噻唑烷酮/噻唑作为优先结构和硫代氨基脲环类似物是新型抗锥虫药物设计中众所周知的支架。我们在这里介绍新的杂合分子的设计和合成,这些杂合分子带有由zo基与各种分子片段连接的噻唑烷酮/噻唑核。结构优化导致具有苯基吲哚或苯基咪唑并[2,1- b ] [1,3,4]噻二唑部分的化合物对布鲁氏锥虫和冈比亚锥虫具有优异的抗锥虫活性。生物学研究允许鉴定出亚微摩尔水平的IC 50,良好的选择性指数,对人原代成纤维细胞的相对较低的细胞毒性以及较低的急性毒性的化合物。
Erythropoietin Expression Promoter
申请人:TOHOKU UNIVERSITY
公开号:US20150353489A1
公开(公告)日:2015-12-10
The present invention provides an erythropoietin expression-enhancing agent that can cancel the suppression of erythropoietin production or promote erythropoietin production, and a therapeutic or preventive drug for anemia, a liver function-improving agent, an ischemic injury-improving agent, a renal protective agent, and an insulin secretagogue comprising the erythropoietin expression-enhancing agent. The erythropoietin expression-enhancing agent of the present invention comprises one or more compounds selected from the group consisting of compounds represented by the following general formulas (I), (II), and (III) and pharmaceutically acceptable salts thereof when R
3
is OH.
Agent for Preventing or Ameliorating Hearing Impairment
申请人:Tohoku University
公开号:US20190224165A1
公开(公告)日:2019-07-25
It is to provide an agent for preventing or improving hearing loss, which comprises a low molecular compound which can be produced relatively easily and inexpensively as an active ingredient. One or more compounds selected from the group consisting of compounds represented by the following formulas (I
0
), (II), and (III) and a pharmaceutically acceptable salt of the compounds when R
3
is OH are used as an agent for preventing or improving hearing loss.
An efficient and straightforward two-step procedure for the synthesis of N-1 alkyl/aryl-substituted hydantoins was developed, starting from easily available starting materials. The procedure envisages a highly regiospecific domino condensation/aza-Michael (nucleophilic substitution)/ON acyl migration between activated α,β-unsaturated carboxylic acids or α-haloaryl acetic acids, respectively, and N-tert-butyl-